Objective To provide a new putative target for immunotherapy on osteosarcoma and explore the effect of matrix metalloproteinase-9 (MMP-9) on the formation of soluble MICA protein in osteosarcoma cells. Methods MMP-9 antisense oligonucleotide was transfected to osteosarcoma cells with lipofectamine 2000. MMP-9 mRNA was assessed by RT-PCR. MMP-9 activity and soluble MICA (sMICA) in the culture supernatant was examined by zymography and quantified by ELISA, respectively. Results MMP-9 mRNA expression and gelatin enzymatic activity were inhibited in MMP-9 antisense oligonucleotide group. Comparing with the control group, lower concentration of sMICA was found in MMP-9 antisense oligonucleotide group (P = 0.011). Conclusion MMP-9 may have an effect on the formation of sMICA protein in osteosarcoma. MMP-9 could be regarded as a putative target for immunotherapy in osteosarcoma.

ObjectiveTo investigate the mechanism of the expression of MHC class Ⅰ chain-related A (MICA) in carcinoma of the urinary bladder,the relationship between MICA,nuclear factor-κB ( NF-κB) and p53 expression in bladder cancer was studied.MethodsThe expression of MICA,NF-κB and p53 in a total of 75 cases of urothelial carcinoma tissues and 15 normal mucous membrane tissues of the bladder was evaluated by immunohistochemistry.ResultsThe expression rates of MICA,NF-κB and p53 protein in urothelial carcinoma were 4.08％,85.3％ and 49.3％,respectively.Up-regulation of their expression was found in urothelial carcinoma compared with normal mucous membrane tissues ( P ＜ 0.05 ).MICA expression was positively correlated with NF-κB expression( r =0.256,P =0.027),but negatively correlated with p53 expression( r =- 0.23,P =0.047 ).ConclusionsUp-regulation of MICA expression was detected in bladder cancer.MICA protein may be a new tumor-associated antigen of bladder cancer.MICA expression may be regulated by NF-κB pathway,while p53 pathway may not play a part in MICA up-expression during the urothelial malignant transformation.

Objective To study the effects of prenatal exposure to diethylstilbestrol(DES) on expressions of ACTIN and proliferating cell nuclear antigen(PCNA) in the development of gubernaculum testis of fetal male mice.Methods Pregnant mice were randomly divided into 6 groups and injected with DES subcutaneously from the 9th gestational day to the 17th day at dosages of 0,25,50,100,200 ?g?kg~(-1)?d~(-1) dissolved in 0.2ml dimethyl sulfoxide(DMSO).The mice in the control group were given normal saline alone.The mice were sacrificed and the fetuses were quickly removed for fixation on the 17th day.Histological changes were observed with light microscope by sliced serially in coronal plane.The expressions of ACTIN and PCNA in gubernaculum testis were detected by immunohistochemical methods.Results In experimental groups,the gubernaculum testis of mice was hypoplasia.The expressions of ACTIN and PCNA in gubernaculum testis were lower in the DES treated groups than those in the control group with obvious dose-effect correlation(P

Objective: To analyze the mutations of BRCA1 in 9 Chinese familiar breast cancer patients. Methods: Peripheral blood samples were obtained from 9 patients enrolled from 9 breast cancer families, one normal control, 32 sporadic breast cancer patients and 33 normal donors. DNA extracted from lymphocytes was amplified by polymerase chain reaction (PCR). The 22 exons and partial introns of BRCA1 were screened by PCR denaturing high performance liquid chromatography (PCR-DHPLC) and confirmed by direct sequencing. Results: Among these 9 familiar breast cancer patients, a deleterious mutation was detected in one case in exon 11 (3870delTGTC) which was a 4 base deletion and caused a frameshift in turn. One novel and unique amino acid substitution (E867R) was detected in one case. Eight patients were detected to have a known variation in intron 18 (IVS18+65G→A), and the ratio of this variation detected was 88.9%(8/9). The ratio of this variation was 37.5%(12/32) in sporadic breast cancer patients or 33.3%(11/33) in normal control. This variation was found to be accompanied all the time with a known missense variation in exon 11 (P871L) and a polymorphism in intron 9 (IVS8 57delT). Those three variants were also detected in homozygous in one case, which implies the linkage of the 3 sites. The linkage had not been reported. Two patients had been found with a known polymorphism in exon 13 (S1436S). Another known polymorphism was found in one case (L771L). In addition, intronic variants (IVS2+48C→T, IVS2+133C→T, IVS12+112C→A) were detected. Conclusion: The mutations of BRCA1 in Chinese familiar breast cancer patients are different from the hot spots reported in Caucasian and Jewish. It is important that further study be conducted to seek for specific mutations of this gene or other possible relevant genes in Chinese familiar breast cancer patients.

Objective:To research the efficacy and adverse reactions of compound matrine injection combined with chemotherapy in the patients with advanced gastric cancer. Methods:According to the order of admission, 68 patients with advanced gastric cancer were divided into the observation group (34 cases) and the control group (34 cases). The two groups of patients were given chemo-therapy, and the observation group was treated with compound matrine injection additionally. After 3 months treatment, the curative effect and KPS score before and after the treatment were compared between the two groups. And adverse drug reactions were recorded for the two groups. Results:The total effective rate of the observation group (44. 12%) was significantly higher than that of the control group (20. 59%,P<0. 05). After the treatment, the KPS score of the observation group was significantly higher than that of the con-trol group (P<0. 05). The incidence of adverse drug reactions in the observation group was significantly lower than that in the control group (P<0. 05). Conclusion: The curative effect of compound matrine injection combined with chemotherapy for advanced gastric cancer is notable, which can significantly improve the KPS score and reduce the incidence of adverse reactions, and is worthy of promo-ted use in clinical practice.